511 related articles for article (PubMed ID: 33211252)
1. Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.
Vargas DM; De Bastiani MA; Parsons RB; Klamt F
Mol Neurobiol; 2021 Apr; 58(4):1517-1534. PubMed ID: 33211252
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
[TBL] [Abstract][Full Text] [Related]
3. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
[TBL] [Abstract][Full Text] [Related]
4. Construction of Parkinson's disease marker-based weighted protein-protein interaction network for prioritization of co-expressed genes.
George G; Valiya Parambath S; Lokappa SB; Varkey J
Gene; 2019 May; 697():67-77. PubMed ID: 30776463
[TBL] [Abstract][Full Text] [Related]
5. Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease.
Menke RA; Jbabdi S; Miller KL; Matthews PM; Zarei M
Neuroimage; 2010 Oct; 52(4):1175-80. PubMed ID: 20677376
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Network Analysis of mRNA and Gene Expression Profiles in Parkinson's Disease.
Wang Y; Wang Z
Med Sci Monit; 2020 Mar; 26():e920846. PubMed ID: 32210219
[TBL] [Abstract][Full Text] [Related]
7. Purine metabolism gene deregulation in Parkinson's disease.
Garcia-Esparcia P; Hernández-Ortega K; Ansoleaga B; Carmona M; Ferrer I
Neuropathol Appl Neurobiol; 2015 Dec; 41(7):926-40. PubMed ID: 25597950
[TBL] [Abstract][Full Text] [Related]
8. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
[TBL] [Abstract][Full Text] [Related]
9. Correcting Differential Gene Expression Analysis for Cyto-Architectural Alterations in Substantia Nigra of Parkinson's Disease Patients Reveals Known and Potential Novel Disease-Associated Genes and Pathways.
Ferraro F; Fevga C; Bonifati V; Mandemakers W; Mahfouz A; Reinders M
Cells; 2022 Jan; 11(2):. PubMed ID: 35053314
[TBL] [Abstract][Full Text] [Related]
10. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease.
Ferrer I; Perez E; Dalfó E; Barrachina M
Neurosci Lett; 2007 Mar; 415(3):205-9. PubMed ID: 17284347
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.
Simunovic F; Yi M; Wang Y; Macey L; Brown LT; Krichevsky AM; Andersen SL; Stephens RM; Benes FM; Sonntag KC
Brain; 2009 Jul; 132(Pt 7):1795-809. PubMed ID: 19052140
[TBL] [Abstract][Full Text] [Related]
12. Construction and analysis of the protein-protein interaction networks based on gene expression profiles of Parkinson's disease.
Rakshit H; Rathi N; Roy D
PLoS One; 2014; 9(8):e103047. PubMed ID: 25170921
[TBL] [Abstract][Full Text] [Related]
13. Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra.
Corradini BR; Iamashita P; Tampellini E; Farfel JM; Grinberg LT; Moreira-Filho CA
Biomed Res Int; 2014; 2014():543673. PubMed ID: 25525598
[TBL] [Abstract][Full Text] [Related]
14. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
18. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease.
Simon DK; Lin MT; Zheng L; Liu GJ; Ahn CH; Kim LM; Mauck WM; Twu F; Beal MF; Johns DR
Neurobiol Aging; 2004 Jan; 25(1):71-81. PubMed ID: 14675733
[TBL] [Abstract][Full Text] [Related]
19. Expression signatures of long non-coding RNA in the substantia nigra of pre-symptomatic mouse model of Parkinson's disease.
Jiao F; Wang Q; Zhang P; Bu L; Yan J; Tian B
Behav Brain Res; 2017 Jul; 331():123-130. PubMed ID: 28476570
[TBL] [Abstract][Full Text] [Related]
20. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.
Bossers K; Meerhoff G; Balesar R; van Dongen JW; Kruse CG; Swaab DF; Verhaagen J
Brain Pathol; 2009 Jan; 19(1):91-107. PubMed ID: 18462474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
